Sphingolipid signaling represents one of the most critical lipid-based signaling systems in the central nervous system, regulating cell survival, death, differentiation, proliferation, migration, and inflammatory responses. The sphingolipid pathway centers on the balance between pro-apoptotic ceramides and pro-survival sphingosine-1-phosphate (S1P)—a balance often termed the "ceramide-S1P rheostat." Dysregulation of this balance contributes fundamentally to neurodegeneration in Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's Disease (HD), and Multiple Sclerosis (MS). This pathway has emerged as a promising therapeutic target, with several S1P receptor modulators already approved for clinical use in autoimmune conditions and actively being investigated for neurodegenerative diseases. [@hannun2018] [@mielke2022]
The brain is exceptionally rich in sphingolipids, which constitute 25-30% of total brain lipid content. These lipids serve dual roles—as essential structural components of neuronal and glial membranes and as potent bioactive signaling molecules. The sphingolipid family includes ceramide (the central hub), sphingomyelin, cerebrosides, gangliosides, sulfatides, glucosylceramide, and sphingosine-1-phosphate. Each species has distinct biological functions and disease relevance. [@hannun2018]
Sphingolipid signaling represents one of the most critical lipid-based signaling systems in the central nervous system, regulating cell survival, death, differentiation, proliferation, migration, and inflammatory responses. The sphingolipid pathway centers on the balance between pro-apoptotic ceramides and pro-survival sphingosine-1-phosphate (S1P)—a balance often termed the "ceramide-S1P rheostat." Dysregulation of this balance contributes fundamentally to neurodegeneration in Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's Disease (HD), and Multiple Sclerosis (MS). This pathway has emerged as a promising therapeutic target, with several S1P receptor modulators already approved for clinical use in autoimmune conditions and actively being investigated for neurodegenerative diseases. [@hannun2018] [@mielke2022]
The brain is exceptionally rich in sphingolipids, which constitute 25-30% of total brain lipid content. These lipids serve dual roles—as essential structural components of neuronal and glial membranes and as potent bioactive signaling molecules. The sphingolipid family includes ceramide (the central hub), sphingomyelin, cerebrosides, gangliosides, sulfatides, glucosylceramide, and sphingosine-1-phosphate. Each species has distinct biological functions and disease relevance. [@hannun2018]
The historical discovery of sphingolipids dates back to the late 19th century when the German biochemist Johann L.W. Thudichum identified sphingosine in brain tissue. The term "sphingosine" derives from the Greek word "sphingos" (sphinx), reflecting the enigmatic nature of these lipids at the time. Subsequent research revealed that sphingolipids are not merely structural components but serve as crucial signaling molecules that govern cellular fate decisions. [@hannun2018]
The biosynthesis of sphingolipids begins in the endoplasmic reticulum (ER) through the de novo pathway. The rate-limiting step involves the condensation of L-serine and palmitoyl-CoA by serine palmitoyltransferase (SPT), forming 3-ketosphinganine. This reaction is catalyzed by the SPT complex, which consists of SPTLC1, SPTLC2, and SPTLC3 subunits. Mutations in SPTLC1 and SPTLC2 cause hereditary sensory and autonomic neuropathy type I (HSAN1) through the aberrant production of toxic 1-deoxysphingolipids, demonstrating the critical importance of regulated sphingolipid synthesis for neuronal health. [@djuric2021]
3-Ketosphinganine is subsequently reduced to sphinganine, then N-acylated by ceramide synthases (CerS1-6) to form dihydroceramides. Each ceramide synthase isoform exhibits distinct preferences for fatty acid chain lengths, ranging from C14 to C26. The dihydroceramides are then desaturated by dihydroceramide desaturase (DES1) to yield ceramides. In the brain, CerS1 primarily produces C18-ceramide, while CerS2 generates very long-chain ceramides (C24-C26). These distinct ceramide species have different biological functions and subcellular distributions. [@djuric2021] [@cutler2014]
From the central ceramide hub, the pathway branches to form diverse complex sphingolipids:
The ceramide-S1P rheostat is a fundamental regulatory mechanism that determines cell fate decisions in response to cellular stress. When the balance tips toward ceramide accumulation, cells undergo apoptosis, necrosis, or autophagy. Conversely, when S1P predominates, cells receive pro-survival, anti-apoptotic, and proliferative signals. This rheostat is dynamically regulated by: [@mielke2022] [@ghosh2023]
Ceramide-generating enzymes:
| Component | Function | Neurodegeneration Relevance | Reference |
|-----------|----------|----------------------------|------------|
| Serine Palmitoyltransferase (SPT) | Rate-limiting enzyme in de novo sphingolipid synthesis | Elevated in AD brain, increases ceramide production | [@haughey2020] |
| Ceramide synthases (CerS1-6) | Produce ceramides with different chain lengths (C14-C26) | CerS1 downregulation in AD; CerS2/CerS6 changes in PD | [@zhang2021] |
| Acid sphingomyelinase (ASM/aSMase) | Converts sphingomyelin to ceramide | Activated by Aβ in AD, increased in PD substantia nigra | [@di2022] |
| Neutral sphingomyelinase (nSMase) | Plasma membrane ceramide generation | Involved in ceramide-induced apoptosis | [@van2021] |
| Sphingosine kinases (SPHK1/2) | Phosphorylate sphingosine to S1P | SPHK1 elevated in AD; SPHK2 reduced in PD | [@he2020] |
| S1P phosphatases (SGPP1, SGPP2) | Dephosphorylate S1P back to sphingosine | Dysregulated in neurodegeneration | [@turtle2023] |
| S1P lyase (SPL/SGPL1) | Irreversibly degrades S1P | Reduced SPL activity in AD brain | [@pitters2022] |
| S1P receptors (S1PR1-5) | GPCRs for extracellular S1P signaling | S1PR1-3 expressed in CNS; S1PR4-5 in immune cells | [@zhang2021a] |
| Glucocerebrosidase (GBA/GCase) | Hydrolyzes glucosylceramide to ceramide | GBA1 mutations = strongest genetic risk for PD | [@he2020a] |
Sphingosine-1-phosphate signals through five G-protein-coupled receptors (S1PR1-5), each with distinct expression patterns and signaling outputs. In the central nervous system, S1PR1, S1PR2, and S1PR3 are expressed on neurons, astrocytes, oligodendrocytes, and microglia, while S1PR4 and S1PR5 are predominantly found on immune cells. [@zhang2021a]
| Receptor | Expression | Main Signaling Pathways | Therapeutic Relevance |
|----------|------------|------------------------|----------------------|
| S1PR1 | Oligodendrocytes, neurons, astrocytes | Gi/o → PI3K/Akt, Rac → cell survival, migration | Fingolimod target, MS therapy |
| S1PR2 | Neurons, astrocytes, microglia | Gi/o, Gq → MAPK/ERK, PLC → calcium signaling | Demyelination, neuroinflammation |
| S1PR3 | Neurons, endothelium, astrocytes | Gi/o, Gq → PI3K, PLC → proliferation, migration | Cardiac effects, angiogenesis |
| S1PR4 | T cells, NK cells, B cells | Gi/o → PI3K → immune cell trafficking | Immunosuppression |
| S1PR5 | Oligodendrocytes, NK cells, T cells | Gi/o → Akt, ERK → myelination, immune regulation | Natalizumab target |
Beyond receptor-mediated signaling, S1P exerts intracellular effects through direct interaction with target proteins. intracellular S1P binds to and inhibits histone deacetylases (HDACs), regulating gene expression. Additionally, S1P interacts with the ubiquitin-proteasome system, autophagy regulators, and mitochondrial proteins. These non-canonical actions contribute to S1P's neuroprotective effects. [@he2020]
Elevated ceramide levels in AD brain represent one of the most consistent lipid abnormalities reported in the literature. Studies have documented 2- to 10-fold increases in ceramide concentrations in the frontal cortex, temporal cortex, and hippocampus of AD patients compared to age-matched controls. This accumulation occurs early in disease progression, with elevated ceramides detectable in mild cognitive impairment (MCI) subjects, suggesting a potential role in disease initiation. [@haughey2020] [@mencarelli2012]
Multiple mechanisms drive ceramide accumulation in AD:
Aβ-induced ceramide production: Amyloid-beta oligomers stimulate acid sphingomyelinase (aSMase) activity, leading to ceramide generation from sphingomyelin hydrolysis. This activation occurs through a mechanism involving NADPH oxidase-derived reactive oxygen species (ROS) and subsequent activation of caspase-8. The newly generated ceramide amplifies Aβ toxicity through several mechanisms: [@haughey2020] [@mencarelli2012]
Synaptic dysfunction: Ceramide disrupts glutamate receptor trafficking and signaling at synapses. Exposure of hippocampal neurons to ceramides reduces AMPA receptor trafficking to the postsynaptic membrane and impairs long-term potentiation (LTP). Ceramide also induces dendritic spine loss through activation of RhoA and downstream effector ROCK. [@dinkins2015]
Mitochondrial dysfunction: Ceramide directly induces mitochondrial permeability transition pore (MPTP) opening, release of cytochrome c, and activation of the intrinsic apoptotic cascade. In AD, ceramide accumulation in mitochondrial membranes contributes to bioenergetic deficits and neuronal death. [@dinkins2015]
In contrast to ceramide accumulation, S1P levels and signaling are compromised in AD:
Reduced sphingosine kinase activity: SPHK1 activity is significantly reduced in AD brain tissue, resulting in decreased S1P production. This reduction impairs pro-survival signaling through S1PR1 and S1PR3, which normally activate PI3K/Akt pathways protecting neurons from Aβ toxicity. [@he2020] [@van2010]
S1PR1 downregulation: S1PR1 expression is downregulated in AD brain, particularly in regions vulnerable to neurodegeneration. Loss of S1PR1 signaling removes a critical neuroprotective mechanism that normally promotes neuronal survival and inhibits apoptosis. [@van2010]
Impaired neurogenesis: S1P is essential for neural progenitor cell proliferation and differentiation in the subventricular zone and hippocampal subgranular zone. Reduced S1P signaling contributes to the well-documented adult neurogenesis deficits in AD. [@van2010]
Endothelial dysfunction: S1P regulates blood-brain barrier (BBB) integrity through S1PR1 and S1PR3 on endothelial cells. Reduced S1P signaling in AD compromises BBB function, allowing peripheral inflammatory molecules access to the CNS. [@van2010]
AD is associated with progressive ganglioside depletion. Complex gangliosides (GM1, GD1a, GD1b, GT1b) decrease in cortical and hippocampal regions, while simpler gangliosides (GM3, GD3) accumulate. This shift reflects impaired ganglioside metabolism and has significant consequences: [@cutler2014]
Heterozygous mutations in the GBA1 gene, encoding glucocerebrosidase (GCase), represent the most common genetic risk factor for PD and dementia with Lewy bodies (DLB). Carried by 5-20% of PD patients depending on ethnicity (highest in Ashkenazi Jewish populations), over 300 GBA1 mutations have been identified, with N370S (mild) and L444P (severe) being the most prevalent. Homozygous GBA1 mutations cause Gaucher disease, a lysosomal storage disorder with neuropathic forms exhibiting severe neurodegeneration. [@he2020a]
Molecular mechanisms: GBA1 mutations impair GCase activity, leading to accumulation of glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph) within lysosomes. Elevated GlcCer directly promotes α-synuclein aggregation by stabilizing toxic oligomeric conformations and inhibiting α-synuclein degradation through the autophagy-lysosomal pathway. This establishes a pathogenic feedback loop: α-synuclein aggregates further inhibit GCase trafficking from the ER to lysosomes, worsening GlcCer accumulation and amplifying synuclein pathology. [@he2020a]
Neuron-glia coupling: Recent studies demonstrate neurons synthesize GlcCer using glucosylceramide synthase (UGCG), while astrocytes primarily break down GlcCer via GCase. This metabolic coupling between neurons and glia in sphingolipid homeostasis may contribute to dopaminergic neuron vulnerability in PD. [@he2020a]
Beyond GBA1 mutations, sphingolipid dysregulation contributes to PD through several mechanisms specific to dopaminergic neurons: [@grange2021]
| Strategy | Target | Compound | Status | Reference |
|----------|--------|----------|--------|------------|
| S1PR1 agonists | S1PR1 | PR-139, fingolimod | Preclinical/Phase 2 | [@grange2021] |
| GBA chaperones | GCase | Ambroxol, isofagomine | Clinical trials | [@alecu2013] |
| Substrate reduction | GCS | Venglustat, ibiglustat | Preclinical | [@alecu2013] |
| Ceramide synthesis inhibitors | CerS | Fumonisin B1 | Research | [@grange2021] |
| Sphingosine kinase activators | SPHK | KPL-0309 | Research | [@grange2021] |
Sphingolipid dysregulation in ALS manifests through multiple mechanisms: [@brunati2022]
| Drug | Target | Mechanism | Disease | Status |
|------|--------|-----------|---------|--------|
| Fingolimod | S1PR1,3,4,5 | Agonist | AD | Phase 2 |
| Ozanimod | S1PR1,5 | Agonist | MS | Approved |
| Siponimod | S1PR1,5 | Agonist | MS | Approved |
| Ponesimod | S1PR1 | Agonist | MS | Approved |
| Compound | Target | Mechanism |
|----------|--------|-----------|
| PF-543 | SPHK1 | Inhibitor |
| ABC294640 | SPHK2 | Inhibitor |
| Myriocin | SPT | Inhibitor |
| Fumonisin B1 | CerS | Inhibitor |
| AM095 | S1PR1 | Antagonist |
In Huntington's disease, mutant huntingtin protein disrupts sphingolipid metabolism through transcriptional dysregulation of sphingolipid biosynthetic genes and impaired vesicular trafficking of sphingolipid enzymes. Altered ganglioside composition, particularly GM1 reduction, in the striatum and cortex may contribute to medium-spiny neuron vulnerability and impaired BDNF signaling. [@cutler2014]
In multiple sclerosis, sphingolipid signaling through S1P receptors modulates immune cell trafficking and astrocyte/oligodendrocyte function. Fingolimod (FTY720), a S1P receptor modulator, is an approved MS therapy that works by sequestering lymphocytes in lymph nodes and may also have direct neuroprotective effects through S1PR-mediated signaling on CNS cells. [@zhang2021a]
For GBA1-associated PD and Gaucher disease, several therapeutic strategies aim to restore GCase activity: [@alecu2013]
Inhibitors of acid sphingomyelinase (aSMase) and neutral sphingomyelinase (nSMase) reduce pathological ceramide production. The functional aSMase inhibitor amitriptyline and specific aSMase inhibitors show neuroprotective effects in AD models. De novo ceramide synthesis inhibitors targeting SPT (myriocin analogs) or specific ceramide synthases are under investigation. [@van2021]
S1P receptor agonists (fingolimod, siponimod, ozanimod) and SphK1 activators aim to restore neuroprotective S1P signaling. While primarily developed for MS, these agents show potential neuroprotective effects in AD and PD models by promoting neuronal survival, reducing neuroinflammation, and enhancing autophagy. [@zhang2021a]
GM1 ganglioside administration has been tested in clinical trials for PD and spinal cord injury, with some evidence of symptomatic benefit. LIGA-20 (a semisynthetic GM1 analog) and other ganglioside mimetics are being explored as neuroprotective agents. [@cutler2014]
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
The following diagram shows the key molecular relationships involving Sphingolipid Signaling Pathway in Neurodegeneration discovered through SciDEX knowledge graph analysis: